Cytos Rises After Asthma Drug Succeeds in Trial: Zurich Mover

Cytos Biotechnology AG (CYTN), a Swiss developer of an experimental drug for allergic asthma, rose to the highest price in almost two months after the medicine met its main goals in a patient study.

Cytos climbed 14 percent to 4.44 Swiss francs as of 9:32 a.m. in Zurich, the highest intraday level since Jan. 17. That gives Schlieren, Switzerland-based Cytos a market value of 95.3 million francs ($101 million). More than 137,000 shares were traded in the first half hour, almost three times the three- month daily average. The stock was the biggest gainer on the Swiss Performance Index.

In a trial among 63 patients in Germany, those treated with the drug, CYT003, had improved control of their asthma after treatment with inhaled corticosteroids stopped, while those who received a placebo saw their disease worsen, Cytos said in a statement today. The drug was safe and generally well-tolerated, Cytos said.

Results from a follow-up trial in 360 patients that started in the fourth quarter of last year are expected in the first half of 2014, Cytos said.

To contact the reporter on this story: Simeon Bennett in Geneva at sbennett9@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.